FTC Strikes Deal on Pay-for-Delay Suit with Endo, Refiles Case Against Allergan

The Federal Trade Commission reached an agreement with Endo to settle claims that the company blocked the market entry of Opana ER and Lidoderm generics, and then refiled a lawsuit against Allergan and its former subsidiary Watson Laboratories with identical charges.
Source: Drug Industry Daily